HOUSTON — A federal judge in Houston sentenced a man to 43-months in prison and ordered him to pay restitution after he was convicted of selling a counterfeit cancer drug. Sanjay Kumar, an Indian ...

Randomization enrolled 1841 systemic-therapy–naïve patients within 12 weeks post-surgery to 1 year pembrolizumab plus daily belzutifan or placebo. Disease-free survival improved despite unreached ...

Event-free survival improved substantially with EV/pembrolizumab, including higher 24-month EFS and an HR of 0.53, with median EFS not reached. Overall survival favored EV/pembrolizumab, with median ...

Merck & Co. is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer ...

Merck splits its human-health business into oncology and specialty divisions. Leadership changes aim to prepare for Keytruda’s 2028 patent expiry. Company banks on pipeline growth and recent ...

Merck MRK0.38%increase; green up pointing triangle is shaking up the leadership of its main pharmaceutical unit as the U.S. drugmaker braces for sales pressure later this decade. The Rahway, ...

Merck said on Monday it would split its business into two, creating ⁠a distinct division for its cancer franchise led by blockbuster drug Keytruda while grouping its non-oncology treatments separately ...

Merck to split business into oncology and non-oncology units Split does not involve its animal health division Key patents on Keytruda will begin to expire in 2028 Feb 23 (Reuters) - Merck (MRK.N), ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...